Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody).
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16911291.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We describe a patient with erythrodermic adult T-cell leukaemia/lymphoma resistant to multiple systemic therapies who, on the commencement of daclizumab, a humanized anti-interleukin-2 receptor antibody, developed a rapid and sustained complete response with resolution of previously debilitating erythroderma, suggesting significant activity of this agent in this disease process.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- Immunoglobulin G
- Immunosuppressive Agents
- Sezary Syndrome
- Skin Neoplasms